ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.93
+1.02 (+1.50%)
At close: 4:00PM EDT

68.93 0.00 (0.00%)
After hours: 4:44PM EDT

Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close67.91
Open68.09
Bid66.76 x 800
Ask70.54 x 800
Day's Range68.05 - 69.56
52 Week Range60.27 - 124.22
Volume1,221,881
Avg. Volume970,815
Market Cap7.344B
Beta (3Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-7.87
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est125.22
  • Markit3 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ALNY had net inflows of $3.73 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
    InvestorPlace4 days ago

    Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock

    After upgrading Pfizer (NYSE:PFE) to "Outperform" in January and raising its price target on Pfizer stock to $48 in May, one would think there's nothing else Credit Suisse could so to bolster its bullish case, but there is.Source: Kojach Via FlickrFollowing a meeting with the pharmaceutical giant's top brass just a few days ago, on Thursday, Credit Suisse labeled PFE stock a "top pick." It was apparently one heck of a meeting.The specifics prompting the accolade weren't made crystal clear, though Credit Suisse did note that the company's prospects for new products was compelling. Translation: Whatever stoked Credit Suisse's fires is likely to be in the company's late-stage pipeline, which is admittedly more exciting than it has been in a long while.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Yield REITs to Buy (Even When the Market Tanks) A Brief Look at PfizerIt's not a story that needs a great deal of retelling. It was an unstoppable powerhouse when it had full patent protection of its erectile dysfunction drug Viagra and faced little competition. But, seeing the writing on the wall, the drugmaker allowed Teva Pharmaceutical Industries (NYSE:TEVA) to begin selling a generic version of the drug in 2017. In the meantime, consumer interest in ED drugs has broadly waned.Pfizer is about to lose ground with blockbuster neuropathic pain drug Lyrica too, which lost patent protection last year, threatening to quickly cut its $5 billion in annual sales in half once generic alternatives become available.It's the same story that plays out over and over within the pharmaceutical industry; these organizations must constantly replenish their portfolios with patent-protected drugs, or risk losing ground.It's something Pfizer hasn't done especially well in recent years.Although Pfizer stock has made reliable if choppy progress since turning around with all other stocks in 2009, revenue growth hasn't been overwhelming. The $53.9 billion in sales generated over the course of the past four reported quarters was not remarkable better than the $52.7 billion figure from a year earlier."Pfizer has been working through a dark period with extensive patent expirations," Credit Suisse analyst Vamil Divan said in late January. "That period is now nearing an end." Solid PipelineWhat Pfizer told Credit Suisse at the meeting remains veiled, though when Divan upgraded Pfizer stock early this year he explicitly noted opportunities for several cancer and autoimmune disease drugs along with vaccinations.Two of the drugs Divan had in mind are Vyndaqel and Vyndamax (though they're actually different doses of the same molecule), which combats the buildup for amyloid in the heart.Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) already make similar rival drugs, but their versions are considerably more expensive. Divan foresees peak sales of $2 billion for Vyndaqel, but is willing to entertain a number "significantly larger than that if Pfizer is able to commercialize it successfully."Pfizer has also partnered with Eli Lilly (NYSE:LLY) on the development of a non-opioid arthritis treatment called tanezumab, another one of the 15 game-changing drugs Pfizer believes could be brought to the market within the next five years.Some analysts are looking for modest peak sales of around $500 million, although Cantor Fitzgerald analyst Louise Chen thinks tanezumab could prove to a multi-billion dollar opportunity to replace a significant piece of the existing opioid market.In the meantime, Pfizer aims to widen the uses of already-marketable drugs like Ibrance, Eliquis, and Xeljanz.Ibrance has already become something of a wonder drug. Already approved as a therapy for multiple forms of breast cancer and generating revenue of $4.1 billion last year, expanded labeling could translate into peak annualized revenue of $8 billion before the treatment hits its ceiling.Eliquis (or Apixaban) for blood clots, co-marketed with Bristol-Myers Squibb (NYSE:BMY), and arthritis/ulcerative colitis therapy Xeljanz generated nearly $3.5 billion and more than $1.7 billion worth of revenue for Pfizer last year, respectively, yet both are also in trials for new uses after having proven they're safe and effective.All told, Pfizer's got 23 phase 3 trials underway right now. All of them look promising; most of them appear to have blockbuster potential. Looking Ahead for Pfizer StockIt was self-serving to be sure when CEO Albert Bourla proclaimed in January that Pfizer is sitting on its "greatest pipeline ever."But that doesn't mean he's wrong.Granted, the deterioration of Pfizer stock since December's peak (PFE stock been performing completely contrary to the market for months) says investors don't exactly believe Bourla. The crowd has understandably become a "show me first" mob, willing to wait on the sidelines for proof that the pipeline can do all the company suggests it can do.Credit Suisse's Divan may have the right idea though. The time to step into a great prospect is when its stock is down because the majority of investors aren't convinced and analysts are collectively lukewarm because they're unable to see more than a few months down the road.That's certainly Pfizer stock right now.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Yield REITs to Buy (Even When the Market Tanks) * 5 Great Blue-Chip Stocks to Buy Today * 7 Tech Stocks to Buy That Are Also Perfect for Retirement Compare Brokers The post Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock appeared first on InvestorPlace.

  • Business Wire16 days ago

    Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT (12:20 pm ET) at the Encore Hotel in Las Vegas, Nevada.

  • Can Pfizer Leap Over the Competition With This Potential Blockbuster?
    Motley Fool17 days ago

    Can Pfizer Leap Over the Competition With This Potential Blockbuster?

    It's been nearly seven years since the FDA refused to approve tafamidis's first new drug application, and the field is a lot more crowded now.

  • How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks
    Investor's Business Daily18 days ago

    How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks

    Dow Jones component Pfizer gained approval Monday for a drug that treats a rare heart disease — potentially rivaling new drugs from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.

  • Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come
    Motley Fool18 days ago

    Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come

    Additional drug approvals and launches are on the way.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of ALNY earnings conference call or presentation 1-May-19 12:30pm GMT

    Q1 2019 Alnylam Pharmaceuticals Inc Earnings Call

  • Alnylam Pharmaceuticals Put Buyers Take Profits During Slide
    Schaeffer's Investment Research21 days ago

    Alnylam Pharmaceuticals Put Buyers Take Profits During Slide

    The biopharma stock is selling off on Sanofi news

  • Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
    GuruFocus.com22 days ago

    Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks

    Fund releases 1st-quarter portfolio

  • Regeneron (REGN) to Report Q1 Earnings: What's in Store?
    Zacks22 days ago

    Regeneron (REGN) to Report Q1 Earnings: What's in Store?

    Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter results.

  • Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1
    Zacks22 days ago

    Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1

    Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.

  • Can Alnylam Pharmaceuticals Stock Start Climbing Again?
    Motley Fool22 days ago

    Can Alnylam Pharmaceuticals Stock Start Climbing Again?

    Investors are starting to wonder if there's anything that can lift this stock higher.

  • Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript
    Motley Fool23 days ago

    Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript

    ALNY earnings call for the period ending March 31, 2019.

  • Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
    Zacks23 days ago

    Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

    Alnylam (ALNY) delivered earnings and revenue surprises of 22.83% and 51.68%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press23 days ago

    Alnylam: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.73. Losses, adjusted for stock option expense, were $1.42 per share. The results topped Wall Street expectations. ...

  • Business Wire23 days ago

    Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity

    − Achieved First Quarter 2019 ONPATTRO® Global Net Product Revenues of $26.3 Million with Over 400 Patients on Commercial Product Worldwide –

  • ACCESSWIRE24 days ago

    Alnylam Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Alnylam Pharmaceuticals, Inc. (EXCHANGE: ALNY ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 1, 2019 at 8:30 ...

  • Business Wire24 days ago

    Alnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran)

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced that it has made substantial progress in the global commercialization of ONPATTRO for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The Company has now completed definitive value-based agreements (VBAs) with 10 commercial payers in the United States. With 10 VBAs completed with commercial payers in the U.S., we’re fulfilling our commitment that ONPATTRO is reimbursed based on its ability to deliver outcomes in the real-world setting comparable to those demonstrated in clinical trials,” said Barry Greene, President of Alnylam.

  • Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
    Zacks28 days ago

    Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus

    The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.

  • Business Wirelast month

    Alnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2019 on Wednesday, May 1, 2019, before the U.S. financial markets open. To access the call, please dial 800-289-0438 (domestic) or 323-794-2423 (international) five minutes prior to the start time and refer to conference ID 4935120. To access the replay, please dial 888-203-1112 (domestic) or 719-457-0820 (international) and refer to conference ID 4935120.

  • This Is Why You Shouldn’t Count Regeneron Stock Out
    InvestorPlacelast month

    This Is Why You Shouldn’t Count Regeneron Stock Out

    For many healthcare stocks, April 2019 has been like tech's December 2018. Just 19% of healthcare issues are above their 50-day moving averages. Blame presidential candidate Bernie Sanders. Or blame the Democratic House, which has been holding hearings on a variety of ideas for cutting drug costs. Congress may end the practice of patent "gaming," in which drug companies make small tweaks to drugs in order to extend patent protection.Source: Shutterstock But whatever Congress does, it shouldn't impact Regeneron Pharmaceuticals (NASDAQ:REGN) to the degree it has -- Regeneron stock has plunged nearly 20% from over $400 per share on April 9 to an April 22 opening price of $333. Regeneron's MethodI have long been a fan of Regeneron stock. While most drug companies tie their futures to specific cures, Regeneron has always been focused on their methods for finding drugs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThese include Velocisuite, which offers fast manipulation of mouse DNA, and TRAP, a general method for developing enzyme blockers. Methods mean Regeneron's pipeline can be constantly renewed for a variety of conditions, from cancer to pulmonary disease to chronic pain.Methods matter. Methods get companies ahead of trends.Regeneron doesn't just know this in its research strategy but in its investment strategy. This is evidenced by a recent $800 million deal with Alnylam (NASDAQ:ALNY) to work on RNA interference, controlling how genes are expressed by interfering with messenger RNA that turns DNA sequences into traits.If Alnylam were Regeneron's only big bet, I wouldn't be listening to bullish forecasts about it. But it's not. Regeneron has development deals with many other companies, including Sanofi (NASDAQ:SNY) and Bluebird (NASDAQ:BLUE), because its gene manipulation methodology can bring drugs to markets faster. * 10 High-Yielding Dividend Stocks That Won't Wilt By having a drug development methodology and cash to spend with companies with specific therapies in mind, Regeneron investors get the ability to spread their bet across many therapies and approaches. Drugs Out of FashionUnfortunately, that's not how Regeneron is valued. Instead, analysts follow the fate of specific Regeneron cures in the market, acting like competition for a single "blockbuster" is going to sink REGN stock.Right now, this makes REGN stock a great bargain. Regeneron's return on equity is 28%. Its price-to-earnings ratio is below 16, with investors paying $333 for over $21 per share of earnings. That's bargain territory.Regeneron is expected to earn $5.39 per share on revenues of $1.72 billion when it next reports May 7, but it has lately made a habit of beating earnings estimates, often by a lot. Analysts are whispering it might beat estimates this quarter by 14 cents, but in the last quarter, it beat estimates by $1.24, and the current estimates are lower. The Bottom Line on Regeneron StockI take a long-term view on stocks, looking for the leading edge of technology, where the value added to society is greatest.The current decade has been all about the cloud, which has brought enormous amounts of computing power to desktops and even mobile platforms.The next decade will be about using this power to turn DNA into a computer language that can be read and manipulated. A research methodology can act like an old-style PC operating system in this worldThis is not a guarantee of long-term success. It only means a company is playing the new game in the right way. That's what I like about Regeneron stock. It has method amid the madness.Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in REGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post This Is Why You Shouldn't Count Regeneron Stock Out appeared first on InvestorPlace.

  • Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)
    Insider Monkeylast month

    Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]